Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2015
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It focuses on providing senior secured loans, structured debt with warrants, and equity investments to high-growth, venture capital-backed companies in technology, biotechnology, life sciences, healthcare, and energy sectors. The company also operates two Small Business Investment Company (SBIC) subsidiaries (HT II and HT III).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2015 | Nine Months Ended Sep 30, 2015 | Net Assets (Sep 30, 2015) |
|---|---|---|---|
| Total Investment Income | $47.1 million | $117.8 million | $722.8 million |
| Net Investment Income | $23.6 million | $53.4 million | |
| Net Realized Gain | $6.4 million | $8.4 million | |
| Net Unrealized Depreciation | ($25.9 million) | ($33.0 million) | |
| Net Increase in Net Assets from Operations | $4.1 million | $28.7 million | $10.02 per share |
| Net Asset Value (NAV) per Share | $10.02 | $10.02 | |
| Total Investments (at Value) | $1.152 billion | ||
| Cash and Cash Equivalents | $147.3 million | ||
| Total Liabilities | $609.9 million | ||
| Dividends Declared per Share | $0.31 | $0.93 | $297.3 million |
| Available Liquidity | (Includes cash and credit facilities) |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased to $1.152 billion at September 30, 2015, from $1.021 billion at December 31, 2014. This growth was driven by new fundings and restructures totaling approximately $532 million during the nine-month period.
- Operating Expenses: Total operating expenses increased to $64.4 million for the nine months ended September 30, 2015, compared to $49.9 million in the prior year period. This increase was primarily due to higher employee compensation (variable and stock-based) and general and administrative costs related to recruiting and legal expenses.
- Unrealized Depreciation: The company recorded significant net unrealized depreciation of $33.0 million for the nine months ended September 30, 2015, compared to $18.3 million in the prior year. This was largely attributed to market/yield adjustments on private equity and warrant investments and collateral-based impairments on debt investments.
- Debt Structure: The 2017 Asset-Backed Notes were fully repaid in April 2015 following a rapid amortization event. The company redeemed $20.0 million of its April 2019 Notes in April 2015.
- Equity Transactions: In March 2015, the company completed a public offering of 7.59 million shares, raising approximately $100.1 million in net proceeds. The company also repurchased approximately 423,000 shares for $4.5 million during the period.
Guidance, Outlook, and Risks
- Portfolio Grading: The weighted average investment grading of the debt portfolio increased (worsened) to 2.33 from 2.24 at year-end 2014. This was due to downgrades of six portfolio companies to a "5" rating due to liquidity and performance concerns, partially offset by upgrades of two companies.
- Non-Accrual Status: As of September 30, 2015, six debt investments were on non-accrual status with a cumulative fair value of approximately $25.3 million (up from four investments with $10.6 million fair value at year-end 2014).
- Liquidity and Capital: The company maintains $297.3 million in available liquidity, including $147.3 million in cash and $150 million in available capacity under its Wells and Union Bank credit facilities (subject to borrowing base requirements). The company has fully utilized its $190.2 million capacity under SBA debentures.
- Subsequent Events: Following the reporting period, the company announced the redemption of $40.0 million of its September 2019 Notes. Several portfolio companies completed IPOs (Edge Therapeutics, Cerecor) or were acquired (nContact Surgical, Gazelle, Good Technology).
- Risks: Key risks include the ability of portfolio companies to achieve objectives, the valuation of private investments (Level 3 assets), and compliance with BDC asset coverage requirements. The company noted that effective yields for the remainder of 2015 were expected to normalize following high levels of unscheduled early repayments in Q3.
Investor Verification Checklist
- Unrealized Depreciation Drivers: Verify the specific portfolio companies contributing to the $33 million net unrealized depreciation, particularly the $10.2 million in collateral-based impairments on debt.
- Non-Accrual Exposure: Review the details of the six non-accrual loans ($25.3 million fair value) to assess potential future write-offs or restructuring costs.
- Portfolio Grading Trends: Monitor the trend of the weighted average investment grade (2.33) to gauge credit quality deterioration or improvement in the coming quarters.
- Liquidity Utilization: Confirm the status of the $150 million in available credit facilities and whether borrowing base requirements are being met given the portfolio composition.
- Dividend Sustainability: Assess the coverage of the $0.31 quarterly dividend against Net Investment Income ($0.33 per share for the quarter) and the impact of non-cash PIK income on cash distributions.